Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.55
EW's Cash to Debt is ranked lower than
54% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. EW: 1.55 )
Ranked among companies with meaningful Cash to Debt only.
EW' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 1.42 Max: N/A
Current: 1.55
Equity to Asset 0.58
EW's Equity to Asset is ranked lower than
57% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. EW: 0.58 )
Ranked among companies with meaningful Equity to Asset only.
EW' s Equity to Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.61 Max: 0.85
Current: 0.58
0.4
0.85
Interest Coverage 93.54
EW's Interest Coverage is ranked higher than
50% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. EW: 93.54 )
Ranked among companies with meaningful Interest Coverage only.
EW' s Interest Coverage Range Over the Past 10 Years
Min: 18.97  Med: 63.1 Max: 118.46
Current: 93.54
18.97
118.46
F-Score: 5
Z-Score: 9.36
M-Score: -2.43
WACC vs ROIC
8.89%
29.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.51
EW's Operating margin (%) is ranked higher than
96% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. EW: 26.51 )
Ranked among companies with meaningful Operating margin (%) only.
EW' s Operating margin (%) Range Over the Past 10 Years
Min: 13.99  Med: 22.1 Max: 53.09
Current: 26.51
13.99
53.09
Net-margin (%) 19.22
EW's Net-margin (%) is ranked higher than
92% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. EW: 19.22 )
Ranked among companies with meaningful Net-margin (%) only.
EW' s Net-margin (%) Range Over the Past 10 Years
Min: 10.36  Med: 16.35 Max: 34.92
Current: 19.22
10.36
34.92
ROE (%) 22.63
EW's ROE (%) is ranked higher than
91% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. EW: 22.63 )
Ranked among companies with meaningful ROE (%) only.
EW' s ROE (%) Range Over the Past 10 Years
Min: 14.26  Med: 20.89 Max: 43.42
Current: 22.63
14.26
43.42
ROA (%) 13.68
EW's ROA (%) is ranked higher than
91% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. EW: 13.68 )
Ranked among companies with meaningful ROA (%) only.
EW' s ROA (%) Range Over the Past 10 Years
Min: 8.72  Med: 13.18 Max: 26.03
Current: 13.68
8.72
26.03
ROC (Joel Greenblatt) (%) 80.59
EW's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. EW: 80.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EW' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 41.35  Med: 57.83 Max: 138.73
Current: 80.59
41.35
138.73
Revenue Growth (3Y)(%) 14.80
EW's Revenue Growth (3Y)(%) is ranked higher than
85% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. EW: 14.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EW' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.7  Med: 11.5 Max: 15.1
Current: 14.8
-9.7
15.1
EBITDA Growth (3Y)(%) 14.00
EW's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. EW: 14.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EW' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.2  Med: 16 Max: 57.8
Current: 14
-20.2
57.8
EPS Growth (3Y)(%) 15.10
EW's EPS Growth (3Y)(%) is ranked higher than
68% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EW: 15.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EW' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 20.85 Max: 288.2
Current: 15.1
0
288.2
GuruFocus has detected 2 Warning Signs with Edwards Lifesciences Corp $EW.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EW's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

EW Guru Trades in Q1 2016

Ray Dalio 18,800 sh (New)
Jim Simons 1,665,800 sh (+50.74%)
Pioneer Investments 1,716,295 sh (+8.75%)
RS Investment Management 182,175 sh (+8.23%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Louis Moore Bacon Sold Out
Frank Sands 10,172,988 sh (-6.88%)
Ron Baron 528,665 sh (-20.41%)
Jeremy Grantham 149,328 sh (-30.58%)
Paul Tudor Jones 2,600 sh (-73.60%)
Steven Cohen 13,700 sh (-90.85%)
» More
Q2 2016

EW Guru Trades in Q2 2016

Lee Ainslie 32,300 sh (New)
Joel Greenblatt 5,837 sh (New)
Louis Moore Bacon 2,323 sh (New)
Eaton Vance Worldwide Health Sciences Fund 175,800 sh (New)
Steven Cohen 194,200 sh (+1317.52%)
Paul Tudor Jones 16,686 sh (+541.77%)
Ray Dalio 33,800 sh (+79.79%)
Jim Simons 2,213,800 sh (+32.90%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jeremy Grantham Sold Out
Pioneer Investments 1,703,864 sh (-0.72%)
Frank Sands 9,619,255 sh (-5.44%)
RS Investment Management 91,090 sh (-50.00%)
Ron Baron 30,903 sh (-94.15%)
» More
Q3 2016

EW Guru Trades in Q3 2016

Steven Cohen 337,900 sh (+74.00%)
Louis Moore Bacon 3,570 sh (+53.68%)
Ray Dalio 45,065 sh (+33.33%)
Pioneer Investments 1,762,534 sh (+3.44%)
Eaton Vance Worldwide Health Sciences Fund 213,257 sh (+21.31%)
PRIMECAP Management 560,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Frank Sands 9,035,637 sh (-6.07%)
Lee Ainslie 26,900 sh (-16.72%)
Jim Simons 1,476,406 sh (-33.31%)
Ron Baron 10,762 sh (-65.17%)
» More
Q4 2016

EW Guru Trades in Q4 2016

Ron Baron 40,284 sh (+274.32%)
Lee Ainslie 38,440 sh (+42.90%)
Steven Cohen 476,400 sh (+40.99%)
Eaton Vance Worldwide Health Sciences Fund 269,163 sh (+26.22%)
PRIMECAP Management 560,000 sh (unchged)
Ray Dalio Sold Out
John Hussman Sold Out
Frank Sands 8,327,338 sh (-7.84%)
Pioneer Investments 1,512,359 sh (-14.19%)
Jim Simons 865,200 sh (-41.40%)
» More
» Details

Insider Trades

Latest Guru Trades with EW

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3842
Compare:NYSE:STJ, NYSE:ZBH, OTCPK:SNNUF, NAS:ISRG, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, NYSE:VAR, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:CNVVY, NAS:ABMD, NYSE:BSX, NAS:NUVA, NAS:MASI, OTCPK:FSPKF, OTCPK:EKTAY, NAS:IART, OTCPK:GGNDF, NAS:WMGI » details
Traded in other countries:EWL.Germany, EW.Switzerland,
Edwards Lifesciences Corp technologies that treat structural heart disease and critically ill patients. It manufactures heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.

Edwards Lifesciences Corp was incorporated in Delaware on September 10, 1999. The Company is the manufacturer of heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. It is also a leader in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. It conducts operations all over world and is managed in the following geographical regions: United States, Europe, Japan and Rest of World. The products and technologies provided by the Company to treat cardiovascular disease or critically ill patients are categorized into the following main areas: Surgical Heart Valve Therapy, Transcatheter Heart Valves, and Critical Care. The Company's Surgical Heart Valve Therapy portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The portfolio also includes a diverse line of cardiac surgery systems used during minimally invasive surgical procedures, and cannulae, embolic protection devices and other products used during cardiopulmonary bypass. The Company's Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. In the Critical Care portfolio, Edwards Lifesciences' products include pulmonary artery catheters, disposable pressure transducers and monitoring systems. The portfolio also includes a line of balloon catheter-based vascular products, surgical clips and inserts. The Company competes with many companies, including divisions of companies much larger than it and smaller companies that compete in specific product lines or certain geographies. The Company's Surgical Heart Valve Therapy and Transcatheter Heart Valve products are manufactured in California and Utah in the United States, Switzerland, and Singapore. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic. The Company's products and technologies are subject to regulation by numerous domestic and foreign government agencies, including the FDA, and various laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of its products and technologies.

Guru Investment Theses on Edwards Lifesciences Corp

Baron Opportunity Fund Comments on Edwards - Feb 21, 2017

Edwards (NYSE:EW) is the world’s leading manufacturer of tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. Edwards has leveraged the knowledge and experience from its surgical tissue heart valve business to develop transcatheter heart valve replacement technologies, designed to treat heart valve disease using catheter-based approaches as opposed to open surgery. Transcatheter aortic valve replacement (TAVR) is an innovative procedure in which a valve is inserted through a catheter and implanted within the diseased aortic valve. The procedure is significantly less invasive than surgery, takes about 90 minutes and recovery can be as short as a few days. TAVR is transforming the market because it provides a new, less invasive treatment option for patients ineligible for surgery or at high surgical risk. Edwards believes there are about 650,000 aortic stenosis patients addressable with TAVR–over twice their prior view of the addressable market–only a fraction of which are being treated with TAVR today. Edwards is also investing in transcatheter valve technologies to treat patients with mitral and tricuspid diseases–which present large, untapped addressable markets (2.5 million for mitral and 1.5 million for tricuspid)–and have the potential to open up significant new growth opportunities for the company.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Edwards Lifesciences Corp

Baron Opportunity Fund Comments on Edwards Guru stock highlight
Edwards (NYSE:EW) is the world’s leading manufacturer of tissue heart valves and repair products, which are used to replace or repair a patient’s diseased or defective heart valve. Edwards has leveraged the knowledge and experience from its surgical tissue heart valve business to develop transcatheter heart valve replacement technologies, designed to treat heart valve disease using catheter-based approaches as opposed to open surgery. Transcatheter aortic valve replacement (TAVR) is an innovative procedure in which a valve is inserted through a catheter and implanted within the diseased aortic valve. The procedure is significantly less invasive than surgery, takes about 90 minutes and recovery can be as short as a few days. TAVR is transforming the market because it provides a new, less invasive treatment option for patients ineligible for surgery or at high surgical risk. Edwards believes there are about 650,000 aortic stenosis patients addressable with TAVR–over twice their prior view of the addressable market–only a fraction of which are being treated with TAVR today. Edwards is also investing in transcatheter valve technologies to treat patients with mitral and tricuspid diseases–which Read more...
Edwards Lifesciences Director Buys 3,000 Shares Company increased revenue and gross profits at a solid rate over the last 10 years
Kieran Gallahue, director of Edwards Lifesciences (NYSE:EW), purchased 3,000 shares of the company for $90.10 per share on Feb. 3 according to a Form 4 filing with the Securities and Exchange Commission. He now owns 9,042 shares of the company. Read more...
Numerous Companies Reach Yearly Highs Recently, a handful of companies achieved 52-week highs
According to GuruFocus list of 52-week highs, these stocks have reached their 52-week highs. Read more...
Vanguard Sells Out Edwards Lifesciences Company's price and P/E ratio near 10-year highs
Vanguard Heath Care Fund sold out its stake in Edwards Lifesciences Corp. (NYSE:EW) in the first quarter. Read more...
Sands Capital Boosts Stake in Edwards Lifesciences Sands Capital buys nearly 9.6 million shares in 4th quarter
Frank Sands' Sands Capital Management boosted its stake in Edwards Lifesciences (NYSE:EW) in the fourth quarter by adding 9,598,997 shares. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 35.34
EW's P/E(ttm) is ranked lower than
60% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. EW: 35.34 )
Ranked among companies with meaningful P/E(ttm) only.
EW' s P/E(ttm) Range Over the Past 10 Years
Min: 11.18  Med: 27.92 Max: 50.58
Current: 35.34
11.18
50.58
Forward P/E 27.25
EW's Forward P/E is ranked lower than
63% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. EW: 27.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 35.34
EW's PE(NRI) is ranked lower than
61% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. EW: 35.34 )
Ranked among companies with meaningful PE(NRI) only.
EW' s PE(NRI) Range Over the Past 10 Years
Min: 11.16  Med: 27.78 Max: 49.62
Current: 35.34
11.16
49.62
Price/Owner Earnings (ttm) 37.39
EW's Price/Owner Earnings (ttm) is ranked lower than
62% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 30.29 vs. EW: 37.39 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
EW' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.88  Med: 33.88 Max: 572.5
Current: 37.39
7.88
572.5
P/B 7.53
EW's P/B is ranked lower than
79% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. EW: 7.53 )
Ranked among companies with meaningful P/B only.
EW' s P/B Range Over the Past 10 Years
Min: 2.9  Med: 5.47 Max: 10.16
Current: 7.53
2.9
10.16
P/S 6.77
EW's P/S is ranked lower than
76% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. EW: 6.77 )
Ranked among companies with meaningful P/S only.
EW' s P/S Range Over the Past 10 Years
Min: 2.32  Med: 4.57 Max: 9.41
Current: 6.77
2.32
9.41
PFCF 41.21
EW's PFCF is ranked lower than
78% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. EW: 41.21 )
Ranked among companies with meaningful PFCF only.
EW' s PFCF Range Over the Past 10 Years
Min: 7.83  Med: 37.79 Max: 593.7
Current: 41.21
7.83
593.7
POCF 28.50
EW's POCF is ranked lower than
81% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. EW: 28.50 )
Ranked among companies with meaningful POCF only.
EW' s POCF Range Over the Past 10 Years
Min: 7.34  Med: 25.24 Max: 48.74
Current: 28.5
7.34
48.74
EV-to-EBIT 26.30
EW's EV-to-EBIT is ranked lower than
54% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. EW: 26.30 )
Ranked among companies with meaningful EV-to-EBIT only.
EW' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 20.2 Max: 39.7
Current: 26.3
6.8
39.7
EV-to-EBITDA 24.02
EW's EV-to-EBITDA is ranked lower than
66% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. EW: 24.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
EW' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 16.1 Max: 33.5
Current: 24.02
6.4
33.5
PEG 1.55
EW's PEG is ranked higher than
68% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. EW: 1.55 )
Ranked among companies with meaningful PEG only.
EW' s PEG Range Over the Past 10 Years
Min: 0.45  Med: 1.37 Max: 3.46
Current: 1.55
0.45
3.46
Shiller P/E 57.35
EW's Shiller P/E is ranked lower than
57% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 49.62 vs. EW: 57.35 )
Ranked among companies with meaningful Shiller P/E only.
EW' s Shiller P/E Range Over the Past 10 Years
Min: 34.67  Med: 62.03 Max: 118.59
Current: 57.35
34.67
118.59
Current Ratio 4.21
EW's Current Ratio is ranked higher than
72% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. EW: 4.21 )
Ranked among companies with meaningful Current Ratio only.
EW' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.67 Max: 5.24
Current: 4.21
1.26
5.24
Quick Ratio 3.46
EW's Quick Ratio is ranked higher than
75% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. EW: 3.46 )
Ranked among companies with meaningful Quick Ratio only.
EW' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.03 Max: 4.54
Current: 3.46
0.9
4.54
Days Inventory 170.43
EW's Days Inventory is ranked lower than
65% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. EW: 170.43 )
Ranked among companies with meaningful Days Inventory only.
EW' s Days Inventory Range Over the Past 10 Years
Min: 132.4  Med: 170.89 Max: 208.39
Current: 170.43
132.4
208.39
Days Sales Outstanding 45.01
EW's Days Sales Outstanding is ranked higher than
73% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. EW: 45.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
EW' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.74  Med: 54.46 Max: 69.95
Current: 45.01
38.74
69.95
Days Payable 44.45
EW's Days Payable is ranked lower than
68% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. EW: 44.45 )
Ranked among companies with meaningful Days Payable only.
EW' s Days Payable Range Over the Past 10 Years
Min: 33.96  Med: 45.59 Max: 63.34
Current: 44.45
33.96
63.34

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.70
EW's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. EW: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EW' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.2  Med: 0.5 Max: 2.2
Current: 0.7
-1.2
2.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 56.57
EW's Price/Net Current Asset Value is ranked lower than
94% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. EW: 56.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EW' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 11.43  Med: 17.84 Max: 78.4
Current: 56.57
11.43
78.4
Price/Tangible Book 11.03
EW's Price/Tangible Book is ranked lower than
81% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. EW: 11.03 )
Ranked among companies with meaningful Price/Tangible Book only.
EW' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.39  Med: 9.61 Max: 29.16
Current: 11.03
6.39
29.16
Price/Projected FCF 2.29
EW's Price/Projected FCF is ranked lower than
56% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. EW: 2.29 )
Ranked among companies with meaningful Price/Projected FCF only.
EW' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.5  Med: 2.11 Max: 3.33
Current: 2.29
1.5
3.33
Price/DCF (Earnings Based) 1.24
EW's Price/DCF (Earnings Based) is ranked higher than
91% of the 22 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. EW: 1.24 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.48
EW's Price/Median PS Value is ranked lower than
80% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. EW: 1.48 )
Ranked among companies with meaningful Price/Median PS Value only.
EW' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 0.64 Max: 1.53
Current: 1.48
0.27
1.53
Price/Peter Lynch Fair Value 1.49
EW's Price/Peter Lynch Fair Value is ranked higher than
55% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. EW: 1.49 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
EW' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.68  Med: 1.4 Max: 3.13
Current: 1.49
0.68
3.13
Price/Graham Number 4.16
EW's Price/Graham Number is ranked lower than
76% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. EW: 4.16 )
Ranked among companies with meaningful Price/Graham Number only.
EW' s Price/Graham Number Range Over the Past 10 Years
Min: 2.34  Med: 3.68 Max: 32.25
Current: 4.16
2.34
32.25
Earnings Yield (Greenblatt) (%) 3.83
EW's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. EW: 3.83 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EW' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.5  Med: 5 Max: 14.7
Current: 3.83
2.5
14.7
Forward Rate of Return (Yacktman) (%) 26.07
EW's Forward Rate of Return (Yacktman) (%) is ranked higher than
89% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. EW: 26.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EW' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 15  Med: 22.6 Max: 37.4
Current: 26.07
15
37.4

More Statistics

Revenue (TTM) (Mil) $2,964
EPS (TTM) $ 2.61
Beta0.89
Short Percentage of Float1.24%
52-Week Range $81.12 - 121.75
Shares Outstanding (Mil)212.50

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,294 3,617 3,780
EPS ($) 3.39 3.90 4.19
EPS w/o NRI ($) 3.39 3.90 4.19
EPS Growth Rate
(3Y to 5Y Estimate)
15.13%
Dividends Per Share ($)
» More Articles for EW

Headlines

Articles On GuruFocus.com
Baron Opportunity Fund Comments on Edwards Feb 21 2017 
Edwards Lifesciences Director Buys 3,000 Shares Feb 07 2017 
12 Best Stocks for Value Investors This Week Feb 05 2017 
Weekly Top Insider Buys Highlight for the Week of Dec. 2 Dec 04 2016 
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 
Numerous Companies Reach Yearly Highs Oct 03 2016 
7 Stocks with Strong Returns and Profitability Aug 04 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 

More From Other Websites
Ultimate Stock-Pickers: Top 10 High-Conviction and New-Money Purchases Feb 22 2017
Edwards' 'Restart' On CardiAQ Heart-Valve Sets Up 2018 Europe Launch: RBC Feb 21 2017
Medtronic Posts 'Quickest Comeback' On Heart-Valve, Brain Therapies Feb 21 2017
Baron Opportunity Fund Comments on Edwards Feb 21 2017
EDWARDS LIFESCIENCES CORP Files SEC form 10-K, Annual Report Feb 17 2017
Edwards Lifesciences Director Buys 3,000 Shares Feb 07 2017
EDWARDS LIFESCIENCES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 07 2017
Stocks End Lower As Facebook Reverses: Amazon Falls After Hours Feb 02 2017
Edwards Lifesciences downgraded by Leerink Partners Feb 02 2017
No "Sophomore Slump" Ahead For Boston Scientific Feb 02 2017
2017 Promises To Be An Interesting Year For Edwards Lifesciences Feb 02 2017
Edwards Lifesciences Sinks 9%; Is This A Buying Opportunity? Feb 02 2017
Edwards Lifesciences Corp. :EW-US: Earnings Analysis: 2016 By the Numbers : February 2, 2017 Feb 02 2017
Edwards Lifesciences Corp. :EW-US: Earnings Analysis: Q4, 2016 By the Numbers : February 2, 2017 Feb 02 2017
Edwards Lifesciences (EW) Beats on Earnings & Sales in Q4 Feb 02 2017
Edited Transcript of EW earnings conference call or presentation 1-Feb-17 10:00pm GMT Feb 01 2017
Edwards Lifesciences beats Street 4Q forecasts Feb 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)